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To identify mechanisms underlying oxaliplatin resistance, a subline of the human gastric adenocarcinoma TSGH cell line, S3, was made
resistant to oxaliplatin by continuous selection against increasing drug concentrations. Compared with the parental TSGH cells, the S3
subline showed 58-fold resistance to oxaliplatin; it also displayed 11-, 2-, and 4.7-fold resistance to cis-diammine-dichloroplatinum (II)
(CDDP), copper sulphate, and arsenic trioxide, respectively. Interestingly, S3 cells were fourfold more susceptible to 5-fluorouracil-
induced cytotoxicity due to downregulation of thymidylate synthase. Despite elevated glutathione levels in S3 cells, there was no
alteration of resistant phenotype to oxaliplatin or CDDP when cells were co-treated with glutathione-depleting agent, l-buthionine-
(S,R)-sulphoximine. Cellular CDDP and oxaliplatin accumulation was decreased in S3 cells. In addition, amounts of oxaliplatin- and
CDDP–DNA adducts in S3 cells were about 15 and 40% of those seen with TSGH cells, respectively. Western blot analysis showed
increased the expression level of copper transporter ATP7A in S3 cells compared with TSGH cells. Partial reversal of the resistance
of S3 cells to oxaliplatin and CDDP was observed by treating cell with ATP7A-targeted siRNA oligonucleotides or P-type ATPase-
inhibitor sodium orthovanadate. Besides, host reactivation assay revealed enhanced repair of oxaliplatin- or CDDP-damaged DNA in
S3 cells compared with TSGH cells. Together, our results show that the mechanism responsible for oxaliplatin and CDDP resistance
in S3 cells is the combination of increased DNA repair and overexpression of ATP7A. Downregulation of thymidylate synthase in S3
cells renders them more susceptible to 5-fluorouracil-induced cytotoxicity. These findings could pave ways for future efforts to
overcome oxaliplatin resistance.
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Platinum drugs represent a class of potent chemotherapeutic
agents. Alone or in combination with other drugs, first-generation
compound cis-diammine-dichloroplatinum (II) (cisplatin, CDDP)
is active against cancers of the lung, ovary, bladder, head and neck,
oesophagus, cervix, and endometrium, and it is curative for the
vast majority of patients with testicular cancer (Einhorn, 1997).
Over the past 30 years, a number of analogues have been
synthesised to enlarge the spectrum of activity, overcome
resistance, and/or reduce toxicity. Oxaliplatin is a third-generation
compound; in contrast to CDDP, it contains a bulky diamino-
cyclohexane (DACH) ring. It differs from other platinum
compounds in several ways. First, oxaliplatin exhibits activity
against colon carcinoma, a prototypical cancer type that shows
primary resistance to CDDP and carboplatin (Misset et al, 2000).
Second, oxaliplatin consistently demonstrates substantial activity
against a variety of CDDP-resistant tumours (Cvitkovic, 1998;
Raymond et al, 1998). Third, oxaliplatin predominantly produces
neurotoxicity rather than nephrotoxicity or myelosuppression
(Extra et al, 1990).
It is commonly accepted that DNA damage is largely responsible
for the cytotoxic properties of platinum compounds. Platinum-
induced DNA adduct formation inhibits DNA replication and
transcription, leading to antiproliferative effects (Sanderson et al,
1996). In vitro studies document significant differences between
oxaliplatin and CDDP regarding the mechanism of action as well as
a diversity in biochemical pathways that protect cells against the
agents (Rixe et al, 1996). The DACH ligand of oxaliplatin might Revised 31 May 2007; accepted 5 June 2007; published online 3 July 2007
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scause steric hindrance to DNA binding (Scheeff et al, 1999), and
evidence suggests that fewer platinum-DNA adduct lesions are
formed for oxaliplatin than for equimolar CDDP (Woynarowski
et al, 1998; Raymond et al, 2002). Even so, oxaliplatin is typically at
least as potent as CDDP in inhibiting growth of cancer cells (Rixe
et al, 1996). These paradoxical findings suggest that DACH–
platinum–DNA adducts more effectively inhibit DNA synthesis.
Cellular resistance to platinum, either intrinsic or acquired, is
encountered regularly during cancer treatment and severely limits
the drugs’ therapeutic potential. Numerous reports have gradually
clarified the major pathways involved in CDDP resistance. Cells
can become resistant to CDDP through reduced drug uptake,
enhanced drug detoxification, augmented DNA repair, and
increased tolerance for DNA damage (Desoize and Madoulet,
2002). The mechanisms of oxaliplatin resistance are less well
established and should never be considered identical to those
underlying CDDP resistance because CDDP chemistry is not
necessarily applicable for oxaliplatin. For example, the bulky
DACH moiety, which is unique to oxaliplatin, might make
platinum–DNA lesions less susceptible to recognition by mis-
match repair systems (Vaisman et al, 1998).
In our current study, we established an oxaliplatin-resistant
subline from a human gastric adenocarcinoma cell line to
investigate the biochemical and molecular mechanisms through
which cells acquire oxaliplatin resistance. Our results show that
combined factors contribute to resistance to oxaliplatin and CDDP.
In addition, downregulation of the thymidylate synthase (TS) gene
in S3 cells renders them more susceptible to 5-fluorouracil (5-FU)-
induced cytotoxicity.
MATERIALS AND METHODS
Reagents
Oxaliplatin was obtained from Sanofi (New York, NY, USA). cis-
Diammine-dichloroplatinum, paclitaxel, 5-FU, l-buthionine-(S,R)-
sulphoximine (BSO), and sodium orthovanadate were purchased
from Sigma Chemical Co. (St Louis, MO, USA). Arsenic trioxide
was purchased from TTY Biopharm (Taipei, Taiwan). Copper
sulphate was purchased from Merck (Darmstadt, Germany).
Primary antibodies to proteins were purchased from the following
companies: ATP7A (BD Transduction Laboratories, Lexington,
KY, USA), ATP7B (Novus, Littleton, CO, USA), excision repair
cross complementation-1 (ERCC-1) (BD PharMingen, San Diego,
CA, USA), TS and glutathione S-transferase-p (GST-p) (Chemicon,
Temecula, CA, USA), a-tubulin (Sigma), and X-ray cross
complementation-1 (XRCC-1) (Neomarkers, Fremont, CA, USA).
Horseradish peroxidase-conjugated secondary antibody was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Establishment of oxaliplatin-resistant cell lines
An established human gastric adenocarcinoma cell line, TSGH, was
cultured in minimal essential medium supplemented with 5% fetal
bovine serum and 100Uml
 1 penicillin, 100mgml
 1 streptomycin,
and glutamate in a humidified 5% CO2 incubator at 371C.
Oxaliplatin-resistant cells were established from TSGH cells by
exposure to increasing concentrations of oxaliplatin. Briefly, TSGH
cells were initially incubated in completed medium containing
0.5mgml
 1 oxaliplatin that yielded 40% cell survival for a period of
3–4 weeks, and the cells that proliferated were repeatedly
subcultured in completed medium containing increasing concen-
trations of the drug (a 20% increment each time). Cells that grew
exponentially in the presence of 2mgml
 1 oxaliplatin were
obtained and subcloned by dilution plating in 48-well plates. Five
individual clones were isolated and designated as S1–S5 cells. For
maintenance, these subclones were cultured under conditions
similar to those used for TSGH, except for a higher concentration
of fetal bovine serum (10%) and addition of oxaliplatin
(2mgml
 1).
Growth inhibition assay
Exponentially growing cells were cultured in 24-well plates.
Resistant cells were maintained in drug-free medium for 3 days
before use. Cells were exposed to various concentrations of drugs
for 72h. The methylene blue dye assay was used to evaluate drug
effects on cell growth as described previously (Finlay et al, 1984).
The drug concentration that inhibited cell growth by 50% (IC50)
was determined after plotting the percentage of growth relative to
untreated control vs drug concentration.
Clonogenic assay
Cells in logarithmic growth phase were cultured in six-well plates
(250cells per well) for one generation (about 27h). Next, cells were
treated with various concentrations of drugs for the indicated
times. Cells were then washed with pre-warmed phosphate-
buffered saline (PBS) twice and maintained in drug-free complete
medium for 9–12 days. At the end of the incubation period, cells
were fixed and stained with 50% ethanol containing 0.5%
methylene blue for 30min, then washed with water. The number
and size of methylene blue-stained colonies were then recorded
and compared with drug-free controls. The assays were carried out
in triplicate. Data were expressed as means7standard deviations.
The LC50 was defined as the drug concentration that produced a
50% decrease in cloning efficiency (ie, 50% lethality).
Determination of cellular reduced glutathione (GSH)
content
Total amounts of cellular GSH were determined using the GSH/
GSSG (GSSG, oxidised glutathione) ratio assay kit (Calbiochem-
Novabiochem, San Diego, CA, USA) following the manufacturer’s
protocol.
Western blot analysis
Crude cellular extracts were prepared for Western blot analysis as
described previously (Kuo et al, 2004). Detection of immuno-
reactive signals was accomplished with the Western Blot Chemi-
luminescent Reagent Plus instrument (Perkin Elmer Life Sciences,
Boston, MA, USA).
Northern blot analysis
Total RNA was isolated from TSGH and S3 cells by the Trizol RNA
isolation method (Life Technologies Inc., Grand Island, NY, USA).
Ribonucleic acid (20mg per lane) was subjected to 1.2% agarose
formaldehyde gel electrophoresis and transferred to a Hybond
N
þ nylon membrane. Membranes were UV cross-linked to
immobilise the RNA. Thymidylate synthase or glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) probes were labelled with
32P using the random primer labelling kit (Stratagene, La Jolla, CA,
USA). For prehybridisation, membranes were placed in Quick
hybrid solution (GE Healthcare Bio-Sciences Corp., Piscataway, NJ,
USA) at 651C for 1–2h. Probes were added and hybridised to RNA
overnight. Membranes were then washed three times with a
solution of 2 saline sodium citrate (SSC), 0.1% sodium dodecyl
sulphate (SDS) at room temperature, and washed three times again
with a solution of 1 SSC, 0.05% SDS at 501C. Wrapped
membranes were exposed to X-OMAT film at  701C. The
expression mRNA level of TS was calculated as the ratio of the
radioactivity in these bands relative to that of the GAPDH bands.
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sSemiquantitative reverse transcriptase–polymerase chain
reaction (RT–PCR)
Ten micrograms of total RNA extracted with Trizol reagent (Life
Technologies Inc.) were treated with DNase and converted to
cDNA using the SuperScript II RNase H
  Reverse Transcriptase
System (Invitrogen, Carlsbad, CA, USA). RT–PCR was performed
on a Perkin-Elmer GeneAmp PCR System 2400 (Applied
Biosystems, Foster City, CA, USA). Polymerase chain reaction
primers and TaqMant probes to amplify the copper transport
protein 1 (CTR1) gene were designed using Primer Express
software version 1.0 (Applied Biosystems), as follows: forward
50-ATTCGGAGAGAGAGGTGCTA-30, and reverse 50-GGAGCAG
GAATCACGTCTT-30. The reaction mixture was preheated at
941C for 5min, followed by 30 cycles at 941C for 1min, 681C for
30s, and 721C for 1.5min. Final extension was at 721C for 7min. In
a separate reaction, GAPDH was amplified as the reference gene.
Platinum accumulation and platinum–DNA adduct assay
Cells (1 10
6) were plated in 100-mm dishes in media without any
drugs and were allowed overnight growth. Cells were left untreated
or subjected to different concentrations of CDDP or oxaliplatin for
4h. After treatment, cells were lysed for protein extraction as
previously mentioned. For DNA extraction, cell pellets were
treated with a genomic DNA purification kit (Promega, Madison,
WI, USA) according to the manufacturer’s protocol. Concentration
of DNA samples was measured at an optometric density of 260nm
(OD260nm) with a Beckman DU 640 spectrophotometer. Platinum
determination was carried out with a Perkin Elmer SCIEX ELAN
6100 ICP–Mass spectrometer (Shelton, CT, USA). The instru-
mental conditions were as follows: RF power 1.5kW; gem-tip
cross-flow nebuliser with Ryton double-path spray chamber;
nebuliser gas flow, 0.99mlmin
 1; dwell time, 200ms; repetition,
5 times. Data were acquired at an atomic mass unit (a.m.u.) of
193.693. Quantitative analysis of samples was performed by the use
of addition calibration as described in the manufacturer’s manual.
Addition calibration provides an effective way to measure samples
through the use of spiked samples. Multi-element Solution 3
(10mgl
 1 Au, Hf, Ir, Pd, Pt, Rh, Ru, Sb, Sn, Te) from Spex
CertiPrep (Metuchen, NJ, USA) was used as the platinum standard.
Student’s t-test was used to compare the mean of each group with
that of the control. A P value o0.05 was considered statistically
significant.
Host cell reactivation assay
Chloramphenicol acetyltransferase (CAT) gene (Promega) was
used on platinum-damaged reporter DNA, whereas pSV b-
galactosidase (b-gal) control vector served as an internal control
for transfection efficiency. Plasmid DNA was treated with either
oxaliplatin or CDDP at 371C followed by ethanol precipitation. The
DNA pellet was washed three times with 70% ethanol, air-dried,
and finally resuspended in Tris-EDTA (TE) buffer. Cells (1 10
6
per dish) were seeded in 100-mm dishes and allowed to grow
overnight. Before use, the plasmid DNA mixture containing 0.5mg
b-gal gene and 1.5mg CAT gene was condensed with buffer
Effectene buffer (buffer EC) and Enhancer (Qiagen, Valencia, CA,
USA) according to the manufacturer’s instructions. The cells were
then transiently transfected with the condensed plasmid DNA
mixture. After a 24-h transfection period, cellular extracts were
prepared and incubated with
14C-labeled chloramphenicol and
butyryl CoA, essentially as described by Ginot et al (1989). After
chromatography, the plate was exposed to X-ray film for an
autoradiogram. Band-specific intensity was quantitated using an
AlphaImager 2000 system. For each transfection, mock-transfected
cells were used as background controls, and non-drug-treated
plasmids were used as positive controls.
Histone H2AX phosphorylation
Histone H2AX phosphorylation was measured by flow cytometry
(Leonce et al, 2006). Cells (1 10
6) were plated in 100-mm dishes
in media without any drugs and were allowed overnight growth.
Cells were exposed to the drugs for 24h, washed, and fixed by 70%
ethanol at  201C for at least 2h. Samples were washed with PBS
and incubated for 5min in PBS containing 0.1% Triton X-100 at
01C. Cells were washed and incubated for 1h at room temperature
with antiphosphohistone H2AX (Ser139) murine monoclonal
antibody (Upstate Biotechnology, Charlottesville, VA, USA). Cells
were washed and incubated for 1h with Rhodamine-conjugated
goat antimouse IgG (Santa Cruz Biotechnology). Cells were
washed, resuspended with 500ml PBS, and analysed by flow
cytometry.
Silencing of TS and ATP7A by small interfering RNA
transfection
For TS silencing, siRNA duplexes were designed to target
sequences on human TS mRNA corresponding to nt 1058-1077
(50-GGAUAUUGUCAGUCUUUAGG-30). The selected sequence is
unique to TS as indicated to a sequence search. Small interfering
RNA duplexes were obtained from Dharmacon (Lafayette, CO,
USA). Each RNA contained two additional 20-deoxythymidine nts
on the 30 end. In addition, a control siRNA duplex, GL2, was
obtained from Dharmacon. The procedure of transfection of
siRNA into cells was as described previously (Schmitz et al, 2004).
For ATP7A silencing, human ATP7A siRNA ON-TARGET plus
SMART pool (mixed four duplex: CAGAAACGAUAAUACGA
UUUU; GAUAAACGCUCCCUAAACAUU; GGUAUUAGCUGUAA
AGUCAUU; GCAAAGGAGUCCAUCAUAUUU, Dharmacon) has
been used in this study. Negative control was pool of four non-
targeting siRNAs: UGGUUUACAUGUCGACUAA; UGGUUUACAU
GUUUUCUGA; UGGUUUACAUGUUUUCCUA; UGGUUUACAU
GUUGUGUGA, Dharmacon). In brief, TSGH cells in exponential
growth phase were plated in six-well plates at 8 10
5 cells per well,
grown for 24h, then transfected with TS siRNA duplex and ATP7A
siRNA ON-TARGET plus SMART pool using cationic lipid
oligofectamine (Invitrogen), respectively, as described by the
manufacturer’s instructions. Silencing was examined 0–72h after
transfection with siRNA-oligofectamine complexes. In addition, a
control siRNA duplex, GL2, was obtained from Dharmacon. For
growth inhibition assay, TSGH cells were plated in six-well plates
at 5 10
4 cells per well for overnight. Small interfering RNA-
oligofectamine complexes were then added to the wells for the
indicated times. Then tested drugs were added to the wells at the
indicated concentrations. The methylene blue dye assay was used
to evaluate drug effects on cell growth after an additional 72-h
(Finlay et al, 1984).
RESULTS
Establishment of a cellular model for oxaliplatin resistance
To compare sensitive and resistant phenotypes in the context of
the same genetic background, we derived sublines from human
gastric adenocarcinoma cell line TSGH that are resistant to
oxaliplatin. After the TSGH cells have been continuously grown
in the presence of step-wise increasing concentrations of
oxaliplatin, five resistant clones (S1–S5) were isolated. Those
resistant clones possessed similar doubling time when compared
to parental cells that is approximately 27h. The stability of
oxaliplatin resistance in those five sublines was determined by
assessing sensitivity after a period of oxaliplatin-free culturing.
Growth inhibition assays conducted 3, 14, and 21 days after
oxaliplatin withdrawal showed no changes in drug sensitivity.
Because the sensitivity to oxaliplatin was similar among those five
Oxaliplatin-resistant human gastric cancer cells
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sclones that are about 55-fold more resistant than the parental cells,
thus, we chose the S3 subclone for further studies.
Assessment of cellular sensitivity of S3 cells to drugs
To evaluate the specificity of the resistance to oxaliplatin, we tested
the sensitivity of the S3 cells to several drugs. The IC50 values are
shown in Table 1. Under our experimental conditions, the S3 cell
line was approximately 58- and 11-fold more resistant to
oxaliplatin and CDDP, respectively. S3 cells were also cross-
resistant to two metalloid-containing agents, copper sulphate and
arsenic trioxide. The IC50 values of S3 cells were approximately
2- and 4.7-fold higher for copper sulphate and arsenic trioxide,
respectively, than those of TSGH cells. Besides, we also found that
S3 cells were four times more susceptible to 5-FU. Both cell lines
exhibited a similar degree of sensitivity to paclitaxel.
Role of GSH and GST-p in modulation of platinum
resistance in S3 cells
Reduced glutathione has been addressed as an important
determinant for platinum resistance. In addition, GST-p has been
addressed as a xenobiotic metabolising enzyme involved in the
detoxification of platinum derivatives. Therefore, the cellular GSH
content and the expression level of GST-p in both parental and S3
cells were determined. As shown in Figure 1A, S3 cells displayed
about a 4.6-fold higher cellular level of GSH. However, there was
no difference in the expression level of GST-p between resistant
and parental cells (Figure 1B).
To clarify further whether the elevated GSH level played a role in
development of platinum resistance in S3 cells, we treated S3 cells
with either oxaliplatin or CDDP in the presence or absence of GSH-
depleting agent BSO for the indicated times and evaluated the
result by clonogenic assay. As shown in Table 2, no alteration of
resistance to either oxaliplatin or CDDP was noted after GSH
depletion.
Changes in the cellular accumulation of platinum,
formation of platinum–DNA adducts, and histone H2AX
phosphorylation in S3 cells
To determine whether the differences in sensitivity to platinum
drugs between TSGH and S3 cells were accompanied by
discrepancies in whole platinum accumulation, both cells were
exposed to various concentrations of oxaliplatin or CDDP for 4h.
As shown in Figure 2A, our data demonstrates that cellular
accumulation of both oxaliplatin and CDDP increases in a dose-
dependent manner. At equimolar concentrations, there was a
significantly higher accumulation of platinum after CDDP
exposure than after oxaliplatin exposure in both TSGH and S3
cells. Besides, there were also significant differences in accumula-
tion of oxaliplatin and CDDP between resistant and sensitive cell
lines. The accumulation of CDDP in S3 cells at the concentration of
100mM was about 35% less than that seen in TSGH cells. S3 cells
also showed less accumulation of oxaliplatin than that of TSGH
cells, but the decrement level was only about 12% at the
concentration of 100mM (Figure 2A).
Because of changes in cellular accumulation of platinum
between TSGH and S3 cells after oxaliplatin or CDDP treatment,
we therefore examined the level of DNA platination in those paired
cells. The total platinum/DNA adduct levels after a 4-h exposure to
oxaliplatin or CDDP are shown in Figure 2B. Comparison of the
Table 1 Cell sensitivity to chemotherapeutic drugs and metalloid-
containing agents in TSGH and S3 cells
IC50 values
a
Drugs TSGH S3 RI
b
Oxaliplatin (mM) 1.4370.08
b 84.174.2 58.7
CDDP (mM) 0.5870.03 6.770.2 11.6
Copper sulphate (mM) 167.074.3 328.2719.9 1.97
Arsenic trioxide (mM) 5.070.5 23.572.9 4.7
5-FU (mM) 15.970.5 4.070.1 0.25
Paclitaxel (nM) 3.071.8 4.272.3 1.4
aCells were treated with various concentrations of test drugs for 3 days. Cell growth
was determined by methylene blue dye assay. The IC50 value resulting from 50%
inhibition of cell growth was calculated. Each value represents the means7s.d. of
three independent experiments.
bResistance index (RI) is calculated as RI¼(IC50 S3
cells)/(IC50 TSGH cells).
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Figure 1 Cellular GSH content and the expression level of GST-p in
TSGH and S3 cells. (A) Total amount of GSH in TSGH and S3 cells was
determined using GSH/GSSG ratio assay kit as described in Materials and
Methods. The data are the means7s.d. of three independent experiments.
(B) Analysis of the expression level of GST-p by using the Western blot
analysis. a-Tubulin has been used as internal control. The results are the
representatives of at least three independent experiments.
Table 2 The effect of BSO, a GSH-depleting agent, on cellular
susceptibility of TSGH and S3 cells to cisplatin and oxaliplatin cytotoxicity
BSO concentration
Cell lines and drugs 0 50lM 100lM
TSGH
CDDP (mM) 0.5470.05 0.6270.07 0.6170.13
Oxaliplatin (mM) 1.5170.17 1.6970.21 1.3970.09
S3
CDDP (mM) 6.5270.3 6.1470.14 7.0170.28
Oxaliplatin (mM) 80.276.9 70.377.5 84.978.8
TSGH and S3 cells were treated with platinum drugs in the presence or absence of
BSO for 24h, then cultured in drug-free medium continuously for 10 days. The LC50
was defined as the concentration of drug that inhibited colony formation by 50%
relative to drug-free controls. Values are means7s.d. of three independent
experiments.
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splatinum/DNA level between oxaliplatin and CDDP indicated that
at equimolar concentration, there was less platinum bound to DNA
after oxaliplatin exposure than after CDDP exposure in both TSGH
and S3 cells. There were also significant differences in the amount
of DNA-bound platinum between resistant and sensitive cell lines.
As seen in Figure 2B, the amounts of oxaliplatin–DNA and
CDDP–DNA adducts in S3 cells were about 85 and 60% less than
those in TSGH cells at the concentration of 100mM oxaliplatin and
CDDP, respectively.
Because more platinum–DNA adducts were formed in TSGH
cells than in S3 cells after platinum treatment, we would like to
determine the frequency of DNA double-strand breaks (DSBs) in
both cells. We found that the levels of gH2AX, a marker of DSBs,
were identical between TSGH and S3 cells in untreated condition
(data not shown). After oxaliplatin and CDDP treatment, the level
of gH2AX in TSGH cells was notably higher than that in S3 cells
(Figure 2C).
ATP7A plays a role in modulation of platinum resistance
in S3 cells
Copper homeostasis plays an important role in the uptake and efflux
of the platinum drugs. Because of changes in the cellular
accumulation of oxaliplatin and CDDP in S3 cells, we therefore
evaluated the expression level of copper transporters to check
whether they were involved in platinum resistance or not. CTR1 is a
main copper uptake transporter in human cells. Our result showed
that the expression level of CTR1 mRNA in S3 cells was about 20%
less than that in parental cells by quantitating band-specific
intensity after adjusting the intensity of GAPDH, the internal
standard (Figure 3A). There was no difference in expression levels of
copper efflux transporter ATP7B between parental and resistant cell
lines in protein level (Figure 3B). However, the expression of copper
efflux transporter ATP7A was about threefold higher in S3 cells than
in parental TSGH cells (Figure 3B).
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Figure 2 Cellular platinum accumulation, platinum-DNA adducts formation, and histone H2AX phosphorylation between TSGH and S3 cells. (A) Cellular
platinum accumulation and (B) Platinum–DNA adducts formation of TSGH and S3 cell lines after exposure to various concentrations (1, 10, 50, 100mM)o f
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before flow cytometric analysis. gH2AX positive cells were quantified and expressed as a function of drug concentration. Error bars show the standard
deviations. * (Po0.05), significantly different for platinum accumulation, DNA adduct formation, and histone H2AX phosphorylation between TSGH and S3
cells at equimolar concentration of platinum drugs.
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sTo further confirm the role of ATP7A in platinum resistance, a
P-type ATPase inhibitor, sodium orthovanadate, was used to
determine whether inhibition of ATP7A function could reverse the
phenotype of drug resistance. TSGH and S3 cells underwent a 1-h
pretreatment with orthovanadate followed by a 72-h treatment
with different concentrations of oxaliplatin and CDDP. As shown
in Table 3, orthovanadate was able to partially reverse oxaliplatin
and CDDP resistance in S3 cells. In addition, we also used RNA
interference system to confirm the role of ATP7A in platinum
resistance. As shown in Figure 4A, treatment of S3 cells with
ATP7A-targeted siRNA was quite effective, resulting in significant
knockdown of cellular ATP7A protein level. The expression of
control protein, a-tubulin, was unaffected by ATP7A-targeted
siRNA treatment (Figure 4A). Treatment with a control GL2 siRNA
had absolutely no effect on levels of ATP7A or a-tubulin.
Consistently, S3 cells transfected with ATP7A-targeted siRNA
were approximately threefold more sensitive to oxaliplatin and
CDDP (Figure 4B). These results indicated that ATP7A plays a role
in modulation of platinum resistance in S3 cells.
Increased DNA-repair capacity in S3 cells
After platinum has formed a large number of adducts on DNA and
converted to DSBs, cell death is still not certain, because cells with
increased DNA repair may be fixing those lesions. To address the
possibility that platinum/DNA adducts are less prone to removal
by repair processes, we analysed the reactivation of oxaliplatin- or
CDDP-treated plasmids in both TSGH and S3 cells. As shown in
Figure 5A, enhanced DNA-repair capacity was found in S3 cells
transfected with either oxaliplatin- or CDDP-damaged plasmids.
After correction with transfection efficiency determined by b-gal
enzyme activity, the DNA repair capacity for oxaliplatin and CDDP
damage in S3 cells was about 26 and 16%, respectively, higher than
in TSGH cells.
Deoxyribonucleic acid repair after platinum adducts’ formation
involves nucleotide excision repair (NER), for which ERCC-1 is a
critical component. In addition, XRCC1 may also be involved in
the repair of other types of DNA damage caused by platinum such
as double-stranded breaks. However, our result demonstrated that
there were no differences in expression levels of ERCC-1 and
XRCC-1 between TSGH and S3 cells (Figure 5B).
Enhanced sensitivity to 5-FU correlated with TS
downregulation in S3 cells
It is interesting to know from Table 1 that S3 cells were more
susceptible to 5-FU than TSGH cells. We thus examined the
expression level of TS protein as well as mRNA in the paired cells.
As shown in Figure 6A, the protein level of TS was about four times
lower in S3 cells than that in TSGH cells. Northern blot analysis
also demonstrated consistent findings.
To further clarify the enhancement of sensitivity to 5-FU in S3
cell whether correlated with downregulation of TS gene, reducing
the TS levels in parent TSGH cells via TS-targeted siRNA
performed in this study. As seen in Figure 6B, knockdown of TS
gene with TS-target siRNA was observed in a time-dependent
manner in TSGH cells. The expression of control protein, a-
tubulin, was unaffected by TS-target siRNA treatment. Treatment
with a control GL2 siRNA had absolutely no effect on levels of TS
or a-tubulin (data not shown). Furthermore, those TS-silencing
TSGH cells were 4.2-fold more sensitive to 5-FU than the mock
control (IC50 5-FU, 3.971.5 vs 16.273.1mM) (Figure 6C).
DISCUSSION
Although evidence of cross-resistance between CDDP and
oxaliplatin exists (Rixe et al, 1996; Safaei and Howell, 2005),
oxaliplatin has been frequently shown to be effective against
tumours with primary or acquired resistance to CDDP (Cvitkovic,
1998; Misset et al, 2000). Conversely, CDDP is rarely tested in
oxaliplatin-resistant cancer cells either in vivo or in vitro. Hector
et al (2001) reported that an oxaliplatin-resistant subline from the
A2780 ovarian cancer cell line demonstrated impaired accumula-
tion of both CDDP and oxaliplatin, hence cross-resistance to
CDDP. Nevertheless, their CDDP-resistant subline exhibited
decreased cellular content of CDDP only, but not oxaliplatin.
Those differences in cellular handling of CDDP and oxaliplatin
raise the question whether mechanisms of resistance between these
two drugs are indeed similar. In contrast to extensive studies of the
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Figure 3 Determination of the expression level of the copper
transporters between TSGH and S3 cell. (A) Analysis of the expression
level of copper uptake transporter CTR1 by using semiquantitative RT–
PCR. GAPDH has been used as internal control. The results are the
representatives of at least three independent experiments. (B) Analysis of
the expression level of copper efflux transporters ATP7A and ATP7B by
using Western blot analysis. a-Tubulin has been used as internal control.
The results are the representatives of at least three independent
experiments.
Table 3 The effect of sodium orthovanadate, a P-type ATPase inhibitor,
on cellular susceptibility of TSGH and S3 Cells to cisplatin and oxaliplatin
cytotoxicity
IC50 values
a
Cell lines and drugs
Without sodium
orthovanadate
treatment
10lM sodium
orthovanadate
Oxaliplatin
TSGH (mM) 1.4770.15 2.2970.22
S3 (mM) 85.477.2 69.172.33
Resistant index
b 58.1 30.2
CDDP
TSGH (mM) 0.5670.05 0.8470.10
S3 (mM) 6.870.2 5.870.3
Resistant index 12.1 6.9
aBoth TSGH and S3 cells were pre-treated with 10mM of sodium orthovanadate for
1h followed by concurrent exposure to either CDDP or oxaliplatin for 72h. Cell
growth was determined by methylene blue dye assay. The IC50 value resulting from
50% inhibition of cell growth was calculated. Each value represents the means7s.d. of
three independent experiments.
bResistance index (RI) is calculated as RI¼(IC50 S3
cells)/(IC50 TSGH cells).
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scellular pharmacology of CDDP, little is known about how cells
become resistant to oxaliplatin. Recent work has identified pivotal
roles of copper transporters in trafficking platinum compounds
through cells and controlling their activities in cells (Safaei and
Howell, 2005). However, most of our knowledge comes either from
CDDP-resistant cell lines or from cell lines manipulated by
transfection with these transporters. To improve the knowledge
of the molecular basis of resistance to oxaliplatin, we generated an
in vitro cellular model of resistance derived from the TSGH gastric
adenocarcinoma cell line, S3, by exposure to increasing concen-
trations of oxaliplatin up to 2mgml
 1. According to the data from
pharmacokinetic study, the peak level in patients receiving
customary 2-h infusion of oxaliplatin at the dose of 85mgm
 2 is
0.814mgml
 1 (Graham et al, 2000; Simpson et al, 2003), which is
much lower than the concentration we used (2mgml
 1). However,
in patients receiving higher dose (130mgm
 2) of oxaliplatin
infusion, the Cmax could reach 2.59–3.22mgml
 1 (Graham et al,
2000), suggesting that although S3 cell line is highly oxaliplatin-
resistant, it is still clinically achievable. In the present study, we
performed a parallel comparison of oxaliplatin-resistant S3 cells
and their parental counterparts in terms of GSH level, drug
accumulation, platinum/DNA adduct formation, and DNA repair
for platinum drugs.
Increased intracellular GSH has been previously associated with
platinum resistance in many studies (Andrews et al, 1985; el-akawi
et al, 1996). In addition, GST-p is a metabolic enzyme which
participates in the detoxification of platinum derivatives and is an
important mediator of both intrinsic and acquired resistance to
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Figure 4 Effect of ATP7A-targeted siRNA on sensitivity of S3 cells towards oxaliplatin and CDDP. (A) Western blot analysis of S3 cells after treatment
with an ATP7A-targeted siRNA. Cells were incubated in the absence or presence of ATP7A siRNA ON-TARGET plus SMART pool for the indicated times,
and harvested and lysed for Western blot analysis. a-Tubulin as internal control. (B) Effect of ATP7A-targeted siRNA on sensitivity of S3 cells towards
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splatinum (Cullen et al, 2003). We determined GSH content and the
expression level of GST-p in resistant and parental cell lines. The
results showed that the level of GSH in S3 cells was 4.6-fold higher
than in parental TSGH cells (Figure 1A), but there was no apparent
discrepancy in the expression level of GST-p protein (Figure 1B).
After treating S3 cells with GSH-depleting agent BSO in the
presence of platinum drugs, no alteration in drug susceptibility
was found (Table 2). This suggests that depletion of GSH is not
enough to overcome the oxaliplatin as well as CDDP resistance in
this model. The modulation of platinum resistance in S3 cells may
be through pathways irrelevant with GSH content.
The results obtained from platinum accumulation assay
disclosed that cellular concentration of CDDP and oxaliplatin
decreased by about 35 and 12%, respectively, in S3 cells when
compared to parental TSGH cells (Figure 2A). The reduced
intracellular concentration of platinum drugs can be either due to
decreased uptake, increased export, or both. Emerging evidence
has shown that mechanisms involved in copper homeostasis play
important roles in platinum transportation through cells (Komatsu
et al, 2000; Ishida et al, 2002; Samimi et al, 2003). One of the
earliest hints that copper homeostasis mechanisms might be
involved in resistance to the platinum drugs was the observation
that cells resistant to platinum drugs are cross-resistant with other
metal or metalloid-containing agents (Naredi et al, 1995; Shen
et al, 1998). In our oxaliplatin model, we found that S3 cells were
cross-resistant to copper sulphate and arsenic trioxide (resistance
index, 2 and 4.7, respectively) (Table 1). Coupled with findings that
cells selected for resistance to platinum drugs are cross-resistant to
copper and vice versa, copper transporters have gradually gained
notice in the search for pathways involved in platinum resistance
(Safaei et al, 2004).
The major copper influx transporter CTR1 has been shown to
assist uptake of CDDP, carboplatin, and oxaliplatin and to regulate
their cytotoxicity in yeast and mammalian cells (Ishida et al, 2002;
Lin et al, 2002). However, little is known about whether CTR1 also
mediates oxaliplatin pharmacology in human cancer cells or not.
Song et al (2004) recently showed that transfection of CTR1 into a
CDDP-resistant, CTR1-deficient subline of a small-cell lung cancer
cell line enhanced cellular uptake of all platinum compounds and
increased sensitivity to CDDP and carboplatin, but not to
oxaliplatin. Holzer et al (2006) demonstrated that CTR1 controls
the cellular accumulation of CDDP, carboplatin, and oxaliplatin at
low concentrations. However, accumulation of oxaliplatin is not
dependent on CTR1 at higher concentrations. In our study,
semiquantitative RT–PCR analysis revealed only 20% reduction of
CTR1 mRNA level in S3 cells compared with TSGH cells
(Figure 3A). Such minor reduction of CTR1 expression implies
that CTR1 may not be a major determinant of platinum resistance
in S3 cells.
Export of copper from mammalian cells involves two Cu efflux
transporters, ATP7A and ATP7B, which belong to P-type ATPase.
It has been documented that ATP7A and ATP7B sequestered
platinum drugs from the cytoplasm into subcellular compart-
ments, mainly vesicles localized to the trans-Golgi network (TGN)
for subsequent efflux in a manner similar to their effects on copper
(Klomp et al, 1997). This action led to reduced platinum
cytotoxicity (Samimi et al, 2004). Available information consis-
tently provided strong evidence that ATP7B mediates resistance to
platinum drugs by regulating drug efflux, and tumours with higher
ATP7B expression did show an unfavourable response to platinum
drug treatment (Safaei and Howell, 2005). However, most of these
reports explored the association between ATP7B overexpression
and CDDP or carboplatin resistance. The only research group that
manoeuvred an ATP7B-overexpressing fibroblast cell line actually
observed an increased sensitivity to oxaliplatin (Samimi et al,
2004). With the expression level of ATP7B in S3 cells similar to that
in TSGH cells, our results suggest that ATP7B plays no role in
development of oxaliplatin resistance in S3 cells.
Among the three copper transporters, substantially less
information is available regarding the ability of ATP7A to
modulate cellular pharmacokinetics of the platinum drugs. Study
of the cellular pharmacology of copper and CDDP in the ATP7A-
deficient cells demonstrated that lack of ATP7A function was
associated with increased accumulation of both copper and CDDP,
and hypersensitivity to both agents (Samimi et al, 2003). When
transfected with an ATP7A expression vector, these cells were
rendered CDDP resistant (Samimi et al, 2003). Overexpression of
ATP7A was seen in our oxaliplatin-resistant S3 cells (Figure 3B).
To confirm further the role of ATP7A in oxaliplatin resistance in
S3 cells, a P-type ATPase inhibitor, sodium orthovanadate, and
ATP7A-targeted siRNA have been used to determine whether
inhibition of ATP7A function could reverse the phenotype of drug
resistance. We found that sodium orthovanadate was able to
partially reverse oxaliplatin and CDDP resistance in S3 cells
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Figure 6 Enhanced sensitivity to 5-FU correlated with TS down-
regulation in S3 cells. (A) Analysis of TS protein and mRNA levels in TSGH
and S3 cells by Western blotting and Northern blotting, respectively. a-
Tubulin has been used as internal control in Western blotting. Beside,
GAPDH has been used as internal control in Northern blotting. The results
are the representatives of at least three independent experiments. (B)
Western blot analysis of TSGH cells after treatment with a TS-targeted
siRNA. Cells were incubated in the absence or presence of 0.1nM of
TS-targeted siRNA for the indicated times, and harvested and lysed for
western blot analysis. (C) Effect of TS-targeted siRNA on sensitivity of
TSGH cells towards 5-FU. TSGH cells were transiently transfected with
TS-targeted siRNA at concentration of 0.1nM for 12h, then cells were
exposed to 5-FU for another 72h. Cell growth was determined by
methylene blue dye assay. Each value represents the mean of three
independent experiments.
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s(Table 3). Likewise, S3 cells transfected with ATP7A-targeted
siRNA were approximately threefold more sensitive to oxaliplatin
and CDDP (Figure 4B). Our data suggest that overexpression of
ATP7A in S3 cells results in increased binding and sequestration of
platinum drugs, which keeps them away from accessing their key
cytotoxic targets in the nucleus. These results indicate that ATP7A
plays a role in modulation of platinum resistance in S3 cells.
The role of ATP7A in development of platinum resistance in
S3 cells, however, could not be completely validated in our
growth-inhibition assays with pretreatment with sodium ortho-
vanadate and ATP7A-targeted siRNA (Table 3 and Figure 4B). The
modest reduction in resistance ratios raises the possibility that
factors other than ATP7A are involved in mediating oxaliplatin
and CDDP resistance in S3 cells. According to our result, the
amounts of oxaliplatin–DNA and CDDP–DNA adducts in S3 cells
were about 15 and 40% of those seen with TSGH cells, respectively
(Figure 2B). Damia et al (1998) showed that the ability of cells
to repair platinum-induced DNA lesions was an important factor
in determining CDDP cytotoxicity. Reardon et al (1999) also
revealed that both CDDP and oxaliplatin adducts were removed to
a similar extent by the excision repair system. Our host cell
reactivation assay clearly demonstrated that DNA damage repair
was pivotal in increased cellular resistance to oxaliplatin. After
transfection, both CDDP- and oxaliplatin-damaged plasmids were
repaired more efficiently in S3 cells than in TSGH cells. The
increments of DNA repair in S3 cells were about 26 and 16% for
oxaliplatin- and CDDP-induced DNA damage, respectively
(Figure 5A).
Histone H2AX has been implicated in the maintenance of
genomic stability by participating in the repair of DNA damage
(Davalos and Campisi, 2003; Sengupta et al, 2004). The
phosphorylation of histone H2AX on Ser139 by the ataxia
telangiectasia mutated (ATM) and ATR (ATM and Rad 3 related)
kinases is an early event observed after the generation of DSBs by
ionising radiation or DNA-cross-linking agents (Rogakou et al,
1998; Banath and Olive, 2003). Thus, we used phosphorylated
histone H2AX (gH2AX) as a marker to compare the induction of
DSBs by oxaliplatin and CDDP to see whether differences existed
between TSGH and S3 cells. Consistently, less DSBs was observed
in platinum-treated S3 cell (Figure 2C).
Nucleotide excision repair, a network of many proteins gathered
in a DNA repair system, is one of the major pathways responsible
for drug resistance. Excision repair cross complementation-1 plays
a pivotal role in NER pathway, influencing the repair of platinum/
DNA damage because of its adducts recognition and excision
ability (Lee et al, 1993). It has been indicated that subjects with
lower ERCC-1 levels had lower DNA repair capacity (Rosell et al,
2003). On the other hand, XRCC-1 has been shown to be involved
in the repair of other types of DNA damage caused by CDDP
including double-stranded breaks (Weaver et al, 2005). To gain
insights into the molecular basis for enhanced repair in our model
system, we measured the expression levels of both ERCC-1 and
XRCC-1 in TSGH and S3 cells. Both proteins were not differentially
expressed in the paired cell lines (Figure 5B). Further studies might
be necessary to determine how the repair system works to protect
cancer cells from platinum-induced cytotoxicity by mending DNA
lesions.
Other than the mechanism of platinum resistance, it is
interesting to find that cells resistant to oxaliplatin and CDDP
show enhanced sensitivity to 5-FU in S3 cells (Table 1).
Thymidylate synthase is the target enzyme of 5-FU (Peters et al,
1994), and it is now well known that decreased TS gene and protein
expression correlates with better clinical responsiveness of color-
ectal and gastric cancers to 5-FU treatment (Johnston et al, 1995;
Lenz et al, 1996). Our TSGH gastric cancer cells that had been
rendered oxaliplatin resistant exhibited significantly decreased TS
protein level, which resulted in enhanced susceptibility to 5-FU
cytotoxicity (Table 1 and Figure 6A, right). The enhanced
sensitivity to 5-FU and decreased expression level of TS protein
were seen not only in S3 cells, but also in the other selected
oxaliplatin-resistant clones, suggesting that change in 5-FU
sensitivity/TS status was reproducible in our system (data not
shown).
We further demonstrated that downregulation of TS protein
expression was the result of decreased level of the corresponding
mRNA (Figure 6A, left). Moreover, we also showed that TSGH cells
could become more sensitive to 5-FU through gene silencing via
TS-targeted siRNA method (Figure 6B), which validated the
important role of downregulated TS gene in rendering S3 cells
more sensitive to 5-FU (Figure 6C). Although the detailed
mechanism for oxaliplatin-induced TS gene downregulation needs
to be further elucidated, our result is concordant with two previous
reports (Raymond et al, 2002; Yeh et al, 2004), which indicated
that oxaliplatin could downregulate TS in cancer cells and thus
potentiate the efficacy of 5-FU. As oxaliplatin and 5-FU have been
shown to be highly synergistic not only in preclinical models
(Raymond et al, 1997) but also in subsequent clinical trials
(Rothenberg et al, 2003; Chao et al, 2004; Lordick et al, 2005;
Schippinger et al, 2005; Cavanna et al, 2006), our data provide
important information regarding why the combination of oxali-
platin and 5-FU results in better objective response than single use
alone.
In conclusion, our study indicates that the mechanisms
responsible for oxaliplatin and CDDP resistance in S3 cells are
overexpression of copper efflux transporter ATP7A and enhance-
ment of DNA repair capacity. Cells rendered oxaliplatin resistant
showed decreased expression of TS gene, which resulted in their
greater vulnerability to 5-FU. Collectively, these findings could
pave ways for future efforts to overcome oxaliplatin resistance.
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